India is deeply committed nationally and globally to achieving all public health goals: J P Nadda


India is deeply committed nationally and globally to achieving all public health goals: J P Nadda 

“India is deeply committed nationally and globally to achieving all public health goals and also focusing on developing India as a hub for affordable medical devices.” This was stated by Shri J P Nadda, Union Minister of Health and Family Welfare at the inauguration of ‘1st World Conference on Access to Medical Products and International Laws for Trade and Health in the Context of the 2030 Agenda for Sustainable Development’, here today. The Health Minister further stated that there is a need for promoting industry and academia collaboration for developing affordable medical products such that innovations and advances in medical sector reach a vast population.

Smt. Anupriya Patel, Minister of State (MOHFW), Dr. V.K. Paul, Member, NITI Aayog, Govt. of India, Smt Preeti Sudan, Secretary, MOHFW, Dr.R.K.Vats, Additional Secretary, MOHFW,Dr.Henk Bekedam, WHO Representative to India, Dr. Soumya Swaminathan, Secretary, Dept. of Health & Research (DHR) and DG, ICMR and Dr. Jagdish Prasad, Director General Health Services,Dr.EMS Natchiappan, President, Indian Society of International Law,  India also graced the occasion.

Shri Nadda stated that the 2015 National Medical Device Policy will enable local manufacture in the multiproduct, multidisciplinary industry. “In India, nearly 150 thousand orthopedic knee procedures are done every day. More investments and more players in the medical devices sector will lead to lowering down of prices and access to medical products as most of the governments are sensitive to access and pricing of medical products,” he added.

Highlighting the importance of transparency between regulatory authorities and pharma sector, Shri Nadda stated that the coordination between the National Regulatory Authorities and pharmaceutical sector will enable launch and registration of new health technologies. He further said that the dialogue on role of competition in competitive pricing and discussion on related WTO agreements influencing health should lead to a larger umbrella of suggested policy options for the government.

Speaking at the function, Smt Anupriya Patel, Minister of State (HFW), stated that India is committed to attainment of the highest possible standards of health for its citizens. She further said that at the national level, access to medical products (medicines, vaccines, medical devices & diagnostics) is an important facet in the health system as a whole and at the international level, access to medical products is a critical factor for the success of the 2030 sustainable development goals agenda that aims to ensure healthy lives and to promote well-being of people of all ages.

Dr. V.K. Paul, Member, NITI Aayog, Govt. of India stated that there is a need for investment in medical products for preventive therapy and treatment and highlighted the importance of affordability, quality, domestic production capacity and to create an eco-system of policy and innovation for greater accessibility of affordable medical drugs and devices. Dr V K Paul further said that technology is an integral block for strengthening medical systems in any country and must also ensure timely maintenance of medical equipment by suppliers in remote and rural areas such that equipment functions effectively.

Smt Preeti Sudan, Secretary, MOHFW spoke about the issues of access of medicines and medical products. She said that safe medical products should be available at affordable prices. She further reiterated that the Health Ministry is committed to robust regulatory systems for ensuring safety, quality and efficacy of drugs.

Dr. Soumya Swaminathan, Secretary (DHR) and DG, ICMR highlighted issues such as how to use TRIPs flexibilities; alternative models for affordable medicines and devices such as voluntary licensing; clear predictable regulatory pathways; more investment in R&D and publicly funded R&D; innovative healthcare service delivery models; anti-biotic stewardship; and collaboration between the public and private sectors including academia to reduce cost of production and delivery.

The Conference is being organized by the Ministry of Health & Family Welfare with the support of WHO Country Office for India and in partnership with Indian Society of International Law. The objective of the Conference is to exchange knowledge and expand understanding on contemporary issues in international trade laws and research and innovation for access to medical products to achieve SDG 2030 agenda.

Also present at the event were,India along with other senior officers of the Ministry, delegates from various countries and representatives of development organizations.

UN High Level Panel on Access to Medicines in the context of SDGs

Session Brief

The Sustainable Development Goal (SDG3) of the Agenda for Sustainable Development has specific targets to support research, development and access to essential medicines and vaccines.

Goal 3. Ensure healthy lives and promote well being for all at all ages

The goals within a goal: Health targets for SDG 3:

Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries provide access to affordable essential medicines and vaccines in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all.

In light of the SDG 2030 Agenda, the United Nations Secretary – General convened a High Level Panel on Innovation and Access to Health technologies with the mandate to review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies which a global problem.

The High-Level Panel (HLP) report addressed four major areas:

       Health Technology Innovation and Access
       Intellectual Property Laws and Access to Health Technologies
       New Incentives for Research and Development of Health Technologies
       Governance, Accountability and Transparency

During the World Health Assembly 2017 discussions on the UN High Level Report on access to medicines, it was decided by all Member States to bring up the matter in the Executive Board of WHO, to inform the proposed special session UN discussions in 2018.

The objective of the session is to enable deeper discussions and a holistic view on access to medicines (including all medical products: medicines, vaccines, devices, diagnostics) and the issues and recommendations made in the UN High Level Panel Report. The following topics are proposed to be discussed to address Access to Medicines (and Medical products) to achieve SDGs:

1.      Governance, Accountability and Transparency
2.      Intellectual Property Laws and Access to Health Technologies
3.      New Incentives for Research and Development of Health Technologies
4.      Health Technology Innovation and Access
5.      WHO’s position and next steps on UN HLP
6.      New Incentives for Research and Development of Health Technologies
7.      Intellectual Property Laws and Access to Health Technologies
8.      Innovation and access to health technologies
9.      Health Policy and Programming


Please enter your comment!
Please enter your name here